Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature
- PMID: 25781697
- DOI: 10.1515/cclm-2015-0058
Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature
Abstract
Generally, calcitonin (CT) values below the upper reference limit rule-out medullary thyroid carcinoma (MTC) with very high accuracy. However, sparse cases of serum-calcitonin-negative MTC (CT-NEG-MTC) have been reported. Here we reviewed CT-NEG-MTC reported in literature, discussed the potential causes and proposed a practical laboratory and clinical approach. A comprehensive literature search was conducted by using the terms "medullary thyroid carcinoma" AND "non-secreting calcitonin" OR "undetectable calcitonin". The search was updated until December 2014. Original articles that described CT-NEG-MTC were eligible for inclusion. Only MTC cases with preoperative CT below the upper reference limit were included in the present review. Eleven papers with 18 CT-NEG-MTC cases (age 50 years, size 26 mm) were retrieved. Four patients with poorly differentiated MTC died within 3 years. Different CT assays were employed and different reference values were adopted. Preoperative serum CT values were below the institution cut-off levels in all cases, and undetectable in four patients. In some papers negative CT results were confirmed by additional tests. Further laboratory investigations were performed in some of the included studies. In patients with well founded suspicious of MTC and within the reference limits/undetectable CT other laboratory investigations [carcinoembryonic antigen (CEA), procalcitonin, CT stimulation, CT in washout of nodule's aspiration] have to be performed. Surgical approach to CT-NEG-MTC does not differ from those secreting CT. Postoperative follow-up of these rare cases should include periodical imaging and measurement of all potential markers. Patients with poorly differentiated MTC are at higher risk of disease-related death, and require more aggressive follow-up strategy.
Similar articles
-
Procalcitonin for detecting medullary thyroid carcinoma: a systematic review.Endocr Relat Cancer. 2015 Jun;22(3):R157-64. doi: 10.1530/ERC-15-0156. Epub 2015 May 1. Endocr Relat Cancer. 2015. PMID: 25934688
-
Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.Diagn Cytopathol. 2016 Jan;44(1):45-51. doi: 10.1002/dc.23375. Epub 2015 Oct 19. Diagn Cytopathol. 2016. PMID: 26481456
-
Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review.Anticancer Res. 2016 Aug;36(8):3803-10. Anticancer Res. 2016. PMID: 27466480
-
Calcitonin and procalcitonin measurement after cholecystokinin-2/gastrin receptor agonist stimulation in patients with advanced medullary thyroid cancer: results from the GRAN-T-MTC study.Endokrynol Pol. 2025;76(3):321-330. doi: 10.5603/ep.106662. Endokrynol Pol. 2025. PMID: 40586407 Clinical Trial.
-
Clinical challenges with calcitonin-negative medullary thyroid carcinoma.J Cancer Res Clin Oncol. 2016 Sep;142(9):2023-9. doi: 10.1007/s00432-016-2169-5. Epub 2016 Apr 28. J Cancer Res Clin Oncol. 2016. PMID: 27125958 Free PMC article. Review.
Cited by
-
Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?BMC Endocr Disord. 2019 May 29;19(Suppl 1):45. doi: 10.1186/s12902-019-0367-2. BMC Endocr Disord. 2019. PMID: 31142313 Free PMC article.
-
Case Report: A Challenging Clinical Problem of Calcitonin-Negative Medullary Thyroid Cancer Diagnosis and Surveillance.Cureus. 2022 Nov 30;14(11):e32088. doi: 10.7759/cureus.32088. eCollection 2022 Nov. Cureus. 2022. PMID: 36600874 Free PMC article.
-
Calcitonin-negative medullary thyroid carcinoma: the 'triple-negative' phenotype.Ann R Coll Surg Engl. 2020 Mar;102(3):e63-e66. doi: 10.1308/rcsann.2019.0153. Epub 2019 Dec 16. Ann R Coll Surg Engl. 2020. PMID: 31841033 Free PMC article.
-
Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma.Front Endocrinol (Lausanne). 2022 Nov 23;13:1025629. doi: 10.3389/fendo.2022.1025629. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36506082 Free PMC article.
-
An Unusual Case of Medullary Thyroid Carcinoma and A Revision of Current Literature.Endocr Metab Immune Disord Drug Targets. 2019;19(2):226-229. doi: 10.2174/1871530319666181220165350. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 30574858 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical